Laurent MEIJER obtained Doctorate degrees from the Universities of Lille (1978) and Paris (1983). After a post-doctoral stay at the Stanford University marine laboratory, Pacific Grove (David EPEL) (1978-1979), he obtained a position at the C.N.R.S. in Roscoff, France. He was on sabbatical leave at the University of Washington, Seattle (Edwin KREBS and Bennett SHAPIRO) (1985-1986) and at the Rockefeller University (Paul GREENGARD) (2001-2004). All his work has focused on basic aspects of protein phosphorylation, as it relates to cancer, neurodegenerative disorders and unicellular parasites. Besides this fundamental research, the group has focused on the identification, optimization and characterization of pharmacological inhibitors of disease-relevant kinases. These efforts have led to the discovery of potent and selective inhibitors of protein kinases (olomoucine, roscovitine, purvalanol, paullones, indirubins, hymenialdisine, aloisines, mériolines, leucettines, etc…). These molecules are widely used as pharmacological tools. They are also undergoing pre-clinical and clinical evaluation against cancers and various neurodegenerative diseases. (R)-roscovitine (CYC202, Seliciclib), is currently in phase 2 clinical trials against NSCL cancer and nasopharyngeal cancer, in phase 1 against renal diseases, and in pre-clinical tests against Alzheimer’s disease, stroke and polycystic kidney disease. To facilitate and speed up the preclinical/clinical development of second generation pharmacological inhibitors of specific kinases, he and Prof. Hervé GALONS (University of Paris Descartes) have founded a small biotech company, ManRos Therapeutics (“From Sea to Pharmacy”) (http://www.manros-therapeutics.com) focused on the development of kinase inhibitors in the treatment of various kidney diseases (short term), cancer & leukaemia (mid-term) and Alzheimer's disease (long term).